Is Valeant The Fix to Salix Inventory Woes?
This article was originally published in The Pink Sheet Daily
Executive Summary
The Canadian pharma is willing to bet $14.5 billion that it can take care of the specialty pharma’s stocking level issues and still pull in $500 million in synergies with in the first six months.